Kornimate/medical-research-clean huggingface dataset:
combining armodafinil with neuro-rehabilitation to improve neurological recovery and reduce disability post-stroke

Conditions: Stroke; Cerebrovascular Accident; Hemiparesis

Summary: armodafinil is an fda approved medication with wakefulness-promoting properties. it is a relatively safe agent with interesting neurochemical effects on the catecholamine system, producing an improvement in cognitive function, particularly working memory in humans. when combined with intensive task-related training, armodafinil may accelerate motor recovery in chronic stroke patients. the primary aim of this study is to determine whether administration of armodafinil during subacute post-stroke rehabilitation will augment cortical plasticity and enhance motor recovery. the primary hypothesis suggests that cortical plasticity will be enhanced by armodafinil and, therefore, will induce an improvement in motor function and better performances on measures of motor control.


Eligibility criteria:
inclusion criteria: * first clinical stroke, either cerebral infarction or intracerebral hemorrhage * severe hemiparesis as measured by a fugl-meyer motor scale score of 0-25 * screening motricity index score of 0-83 * date of stroke onset between 7 to 21 days prior to study inclusion exclusion criteria: * age less than 18 * previous clinical stroke * pregnant and/or nursing patients * major psychiatric history, including psychosis and history of substance abuse * dementia * known cns pathology such as brain tumor * significant language dysfunction or severe neglect that hinders comprehension, participation, and barrier to testing * seizures * left ventricular hypertrophy (lvh) * mitral valve prolapse (mvp) * severe chronic renal failure or severe hepatic failure * history or current use of anti-epileptic medications, psychostimulants, or neuroleptics * current use of diazepam, phenytoin, propranolol, tricyclic antidepressants, steroidal contraceptives, cyclosporine, or theophylline

Keywords: stroke cva cerebrovascular accident hemiparesis impairment motor recovery neuroplasticity nuvigil armodafinil
using smart phone technology to rural veterans

Conditions: Panic Disorders; Anxiety Disorders

Summary: the purpose of this study is to see if a new smart phone application can help veterans manage their panic symptoms after completing a two-day treatment for panic attacks.

the first goal is to see how helpful the smart phone application is in helping veterans with panic symptoms continue to improve after you complete treatment. the second goal of this study is to find out how much veterans like the smart phone application. the third goal is to see how practical it is to use the smart phone application as a form of follow-up care. we want to see how much time is needed to provide technical support in using the application.

Eligibility criteria:
inclusion criteria: participants must 1. be an operation enduring freedom/operation iraqi freedom/operation new dawn (oef/oif/ond) veteran 2. currently meet criteria for pd with or without agoraphobia 3. complete the weekend pd treatment at the lufkin, conroe or texas city cboc. exclusion criteria: 1. current substance dependence 2. organic psychosis 3. symptomatic bipolar disorder 4. severe depression with suicidal intent or plan 5. cognitive impairment (indicated by scores \<20 on slums)

Keywords: panic panic disorder anxiety
tumor antigen-sensitized dc vaccine as an adjuvant therapy for esophagus cancer

Conditions: Carcinoma; Esophagus Cancer

Summary: the aim of this single center, single arm and prospective study is to explore the safety and efficacy of tumor antigen-sensitized dc vaccine in postoperative adjuvant treatment of esophageal cancer.


Eligibility criteria:
inclusion criteria: * pathologically confirmed diagnosis of esophageal squamous cell carcinoma； * immunotherapy for preoperative； * karnofsky performance status 0-1; * the postoperative pathological stage is (y) pt + and / or n + m0 according to ajcc 8th * function of the main organs is normal; * edition patient's written informed consent exclusion criteria: * tumor emergencies; * abnormal coagulation function; * contagious diseases, such as hiv, hbv, hcv infection; * mental disorders; * concomitant tumors; * immunological co-morbidities

Keywords: esophagus cancer tumor neo-antigen dc vaccine safety clinical efficacy
dialysis catheter placement in patients with thoracic central venous occlusion

Conditions: Central Venous Catheter Thrombosis

Summary: a unique inside-out-access technique with a new ce certified device (surfacer (r) bluegrass vascular, san antonio, tx, usa) enables repetitive and confident right-sided placement of central venous catheters in hemodialysis patients with thoracic central venous occlusion.


Eligibility criteria:
inclusion criteria: * patients with thoracic central venous occlusion exclusion criteria: * pregnancy

Keywords: thoracic central venous occlusion dialysis access
preoperative ascites drainage versus standard care for patients with advanced ovarian cancer

Conditions: Ascites; Ovarian Epithelial Cancer; Malnutrition

Summary: patients with significant ascites and advanced ovarian cancer (aoc), undergoing complex, cytoreductive surgery are at risk of malnutrition, poor quality of life and the risk of hypo- or hypervolemia in a perioperative period. all these factors may cause hemodynamic consequences during anesthesia and surgery, and elevate the risk of morbidity and mortality. the objective of the study is to evaluate, whether slow ascites evacuation for a few days before the surgery for aoc, could 1) influence the hemodynamic consequences of ascites on systemic circulation in patients undergoing surgery, 2) improve patient's quality of life and 3) ability to feed correctly before treatment starts, and thus lower the risk of perioperative morbidity. eligible patients are those with significant ascites, diagnosed or suspected for aoc, who are scheduled for primary surgery (both upfront cytoreduction or laparoscopic evaluation before neoadjuvant chemotherapy), that cannot be performed within next 7 or more days, for any reason. patients will be asked to fill in quality of life questionnaire (qlq). clinical data, a subjective global assessment (sga) will be recorded. patients will be randomized to either intervention arm a - insertion of vascular catheter into abdominal cavity and slow, systematic, daily ascites evacuation, or to observation arm b - standard of care with just observation (acute large volume (\>5000ml) paracentesis allowed if needed). patients in both groups will be encouraged to use oral nutritional support. randomization will be open, 1:1, for every eligible, consecutive patient. after 7 days patients will be interviewed, asked to fill in qlq, patient's experience on the treatment survey, a sga will be recorded. during the first hour of the surgery hemodynamic data from anethetic charts will be recorded along with other clinical data concerning patient's characteristics, surgery details and 30-day postoperative follow-up. a template is provided. the hypothesis of the study is that slow, systematic ascites evacuation few days before surgery for advanced ovarian cancer can facilitate hemodynamic control of systemic circulation of patients undergoing surgery, and improve patients' quality of life, feeding ability before treatment starts. secondary we would expect lower risk of perioperative morbidity and mortality.


Eligibility criteria:
inclusion criteria: * patients with significant ascites and suspected ovarian cancer scheduled for upfront cytoreductive surgery, or diagnostic laparoscopy and neoadjuvant chemotherapy, and the surgery is planned to be performed in at least 7 days, * signed informed consent of the patient. exclusion criteria: * ascites not of malignant origin, * low volume ascites, * other then primary ovarian malignancy suspected, * suspected or clinically apparent infection especially at the site of planned drainage placement, * no patient's consent.
randomized double-blind controlled clinical trial

Conditions: Chronic Wounds; Acute Wounds

Summary: the study is a randomized double-blind controlled clinical trial designed to compare the ability of naocl to nss in the reduction of bacterial burden in nonhealing acute and chronic wounds.

the study is a randomized double-blind controlled clinical trial designed to compare the ability of naocl to nss in the reduction of bacterial burden in nonhealing acute and chronic wounds. using the generally accepted surrogate endpoint of surface area reduction at 4 weeks, the study will also compare the healing of subjects utilizing naocl vs. nss. after consenting, the ulcers of eligible subjects are measured, photographed and undergo the moleculight imaging procedure (mix). the subject is then randomized to one of two arms: target ulcer cleansed with naocl or nss. after cleansing the wound a second mix is performed. the subject is given a four-week supply of either naocl or nss.

Eligibility criteria:
inclusion criteria: 1. adult patients with acute or chronic wounds that have been present for a minimum of 4 weeks. 2. a signed and dated informed consent form. 3. subject is willing and able to comply with instructions and scheduled visits. exclusion criteria: 1. the subject has other concurrent conditions that in the opinion of the investigator may compromise subject safety. 2. the subject's wound has not been present for at least 4 weeks.
the effect of emotional support given during cesarean section on pain, anxiety, and surgical fear

Conditions: Emotional Support During Cesarean Delivery

Summary: the study was conducted to determine the effect of emotional support given during cesarean section on pain, anxiety and surgical fear.

the experimental study sample consisted of 120 women (emotional support group: 60, control group: 60). data were collected using the personal information form, visual analog scale, state anxiety inventory and surgical fear scale. in the comparison between the groups in the study, it was found that there was a statistically significant difference between the mean visual analog scale scores of the women in the experimental and control groups in the pre-test (p\<0.05), and no difference in the post-test (p˃0.05). in the post-test measured after emotional support, it was found that there was a statistically significant difference between the state anxiety inventory scores, short-term, long-term and total surgical fear scale scores between the groups (p˂0.05). after emotional support, women's pain levels increased, anxiety and surgical fear levels decreased and their satisfaction with emotional support during birth increased. women who did not receive emotional support had significantly increased pain, anxiety and surgical fear levels.

Eligibility criteria:
inclusion criteria: * women who had a history of spinal anesthesia for the first time during a cesarean delivery, * who were going to have a planned cesarean before spontaneous contractions started, * who had no health problems with their babies, * who had no physical or mental problems themselves, * who had no communication difficulties, * women who volunteered to participate were included in the study. exclusion criteria: * women who had a normal spontaneous delivery, * women who had a cesarean after labor/spontaneous contractions started, * women who had any health problems with their babies, * women who had a physical or mental illness themselves, * women who did not want to participate in the study were not included in the study.

Keywords: caesarean emotional support pain anxiety fear of surgery
gambit trial: cisplatin plus irinotecan in the treatment of gallbladder or biliary tract cancer

Conditions: Biliary Cancer

Summary: to evaluate safety and efficacy of the combination cisplatin plus irinotecan in the treatment of biliary tract cancer.


Eligibility criteria:
inclusion criteria: * biopsy-proven gallbladder or biliary tract cancer; * recurrent, metastatic or unresectable disease; * chemo-naïve. * not candidates to curative-intent treatment, such as surgery or radiation-therapy; * measurable disease according to recist 1.1; * ecog 0-2; * adequate hematologic and biochemistry tests; * creatinine clearance \>= 60ml/min. exclusion criteria: * known hypersensibility or previous therapy with cisplatin, gemcitabine or irinotecan; * chronic immunosuppressive therapy; * known cns metastasis; * previous diagnosis of other cancer; * chronic or acute active infection, except asymptomatic hiv infection; * active bleeding; * any severe medical condition; * pregnant or lactating women, or with childbearing potential;

Keywords: biliary cancer irinotecan cisplatin gemcitabine
the role of root canal treatment in alleviating endodontic pain-induced asymmetry and restoring muscle balance

Conditions: Temporomandibular Disorders (TMD); Acute Apical Periodontitis of Pulpal Origin

Summary: the study hypothesizes that masticatory laterality caused by acute apical periodontitis pain result in muscle asymmetry. furthermore, it posits that successful root canal treatment, by restoring normal bilateral chewing function, will reduce this asymmetry, as evidenced by ultrasonographic measurements of the masseter and anterior temporal muscles.the main question it aims to answer is: can bilateral chewing function be restored after root canal treatment procedures in patients with masticatory laterality due to painful teeth due to acute apical periodontitis?


Eligibility criteria:
inclusion criteria * patients with masticatory laterality due to tooth pain for at least 30 days * first and second maxillary or mandibular molars with acute apical periodontitis due to deep caries * teeth with moderate or severe pain according to the vas (no pain (0 mm), mild pain (1-3 mm), moderate pain (4-6 mm), and severe pain (7-10 mm)) * teeth that responded positively to percussion test * teeth without periapical pathosis were included in the study. exclusion criteria * systemic conditions affecting muscle structure or function, such as neuromuscular or endocrine disorders. * non-endodontic odontogenic pain. * prior endodontic treatment of the relevant tooth within the last 30 days. * history of trauma or surgery to the head, face, or teeth within the last six months. * severe communication disorders or psychological issues. * inability to complete treatment in a single visit due to exudation or bleeding * patients with masticatory laterality due to missing tooth on any side of the dental arch * patients who have painful teeth in opposite sides of the dental arch * tmd patients were excluded from the study.

Keywords: root canal treatment ultrasonography endodontic pain acute apical periodontitis masticatory laterality
study to evaluate chronic myeloid leukemia treatment landscape and real-life treatment outcomes in hungary: analysis of national health insurance fund database

Conditions: Chronic Myeloid Leukaemia

Summary: the objectives of this study are to describe patient demographics, clinical and disease characteristics and treatment patterns of chronic lymphoid leukaemia (cml) in hungary. the primary endpoint of this study is the overall survival of cml patients treated with tyrosine kinase inhibitors in hungary. the overall survival (os) of all enrolled patients, os by sequence pattern and by the number of treatment lines will be analyzed. secondary objectives are description of the treatment length in 1st and later lines, incidence and prevalence of cml, the patient demographics (as age, gender, comorbidities), average number of patients' comorbidities, most frequent comorbidities and patient number with comorbidities at baseline and at different treatment lines by investigated thyrosine kinase inhibitor (tki), distribution of the investigated tki therapies by treatment lines


Eligibility criteria:
inclusion criteria: * female and male patients diagnosed with chronic myeloid leukemia * patients receiving tyrosine kinase inhibitor therapy under the terms of the current marketing authorization exclusion criteria: * patients receiving tki for non-cml diagnoses

Keywords: tyrosine kinase inhibitor (tki)
phase 1 study of the pharmacokinetics of amoxicillin in pregnancy

Conditions: Pregnancy Related

Summary: the study design is a prospective phase i pharmacokinetic study focused on dosing of 500 mg oral amoxicillin administration in pregnant women in the 2nd and 3rd trimester.

twenty adult pregnant women in good health who are admitted for preterm premature rupture of membranes (24-34 weeks gestational age) will be enrolled in this intensive pharmacokinetic study. basic information will be collected from the medical record including age, weight, height, pregnancy dating, medications, and allergies.

Eligibility criteria:
inclusion criteria: 1. pregnant, engaged in prenatal care with a medical provider (at least one visit) 2. estimated gestational age 24-34 weeks 3. able to provide informed consent 4. english speaking exclusion criteria: 1. receipt of amoxicillin within the past 7 days. (routine gbs prophylaxis with ampicillin or other antibiotic and routine surgical prophylaxis prior to cesarean with cephalexin and azithromycin 500 mg iv is allowed). 2. known hypersensitivity or intolerance of amoxicillin, penicillin, other beta lactam or cephalosporin antibiotics. 3. known renal impairment (serum creatinine ≥1.2 mg/dl). 4. active concomitant medications known to interact with amoxicillin: allopurinol, methotrexate, mycophenolate, immune checkpoint inhibitors (ie. pembrolizumab), tetracyclines (ie. doxycycline), vitamin k antagonists (ie. warfarin), aminoglycosides (ie. gentamicin).

Keywords: pharmacokinetics amoxicillin
low-cost imaging technology for global prevention of cervical cancer

Conditions: Cervical Intraepithelial Neoplasia

Summary: cervical cancer remains the first or second leading cause of cancer death among women in many low-and middle-income countries. cervical cancer prevention programs in low-resource settings are hampered by a lack of personnel with appropriate clinical expertise, lack of pathology services, and lack of associated infrastructure. there is an urgent need for appropriate diagnostic tools to enable accurate screening and diagnosis in low-resource settings. the purpose of this study is to develop and validate a low-cost multimodal mobile colposcope (mmc) for global cervical cancer prevention programs. this new device will combine the imaging capabilities of a mobile colposcope with the microscopic imaging capabilities of a fiber-optic confocal imaging probe.


Eligibility criteria:
inclusion criteria: * women \>25 years of age; * women undergoing colposcopy due to abnormal cervical screening or follow-up for a history of dysplasia; * women of childbearing potential must have a negative urine or blood pregnancy test; * ability to understand and willingness to provide informed consent by signing specific informed consent document. exclusion criteria: * women under 25 years of age; * women who have undergone hysterectomy with removal of the cervix; * women with known allergy to proflavine or acriflavine; * women who are pregnant or nursing at the time of enrollment; * incapacitated women or in vulnerable situations or who are not willing to give consent;

Keywords: image analysis cancer prevention cervical intraepithelial neoplasia
polarized light therapy in patients with crest syndrome.

Conditions: CREST Syndrome

Summary: to evaluate the efficacy of the polarized light therapy and hand grip strengthening exercises in patients with crest syndrome

measurement of the skin thickness via the modified rodnon skin score (rss) and hand grip dynamometer (hgd) . methods:- sixty patients, who had hand involvement of patients with crest syndrome, were participated in the study. their ages were ranged from 16 to 45 years. the participants were selected from the dermatology departments of cairo university hospitals and om el-misrieen hospital, randomly distributed into three equal groups. group a: (study group): this group included 20 patients who had crest syndrome with scleroderma in the dorsum of hands and who received the blt with traditional physical therapy program (stretching, strengthening and active exercise) patients received 3 sessions per week for 12 weeks (3 months),time of session is 15 minutes. group b: this group included 20 patients who have crest syndrome with scleroderma in the dorsum of hands and who received resisted exercise with traditional physical therapy program (stretching, strengthening and active exercise) patients received 3 sessions per week for 12 weeks (3 months), time of session is 15 minutes and group c:this group included 20 patients who had crest syndrome with scleroderma in the dorsum of hands and who received combination of (blt and resisted exercise) with traditional physical therapy program (stretching, strengthening and active exercise) exercise program (stretching, strengthening and active exercise).patients received 3 sessions per week for 12weeks (3 months), time of session was 15 minutes.

Eligibility criteria:
inclusion criteria: * the patients' ages ranged from 16 to 21 years. * patients who had hand involvement of patients with crest syndrome particularly dorsum of the hand. * all patients were conscious. * all patients were randomly chosen (male and female). exclusion criteria: * patients who are diabetic or hypertensive. * patients those familiar with the blt and resisted exercise via the hand grip strengthener. * patients with hemorrhage specially hemorrhage of digestive system and those with bleeding per rectum. * patients with severe fungal diseases and acute viral diseases. * patients with active tuberculosis and tumors as well as those with peacemakers. * patients with polyneuropathy. * patients with thyroid problems

Keywords: polarized light therapy resisted exercise crest syndrome modified rodnon skin score and hand grip dynamometer
clinical study of pegaptanib sodium (eye001) for wet-type age-related macular degeneration

Conditions: Macular Degeneration

Summary: this study will examine the safety and efficacy of pegaptanib sodium in japanese patients with wet-type age-related macular degeneration (amd), who benefit further treatment and who want to continue the treatment after completion of the preceding study (a5751010).


Eligibility criteria:
inclusion criteria: * after completion of the preceding study (a5751010) exclusion criteria: * serious heart, kidney and/or liver disease * diabetic retinopathy

Keywords: long-term study for pegaptanib sodium in patients with subfoveal choroidal neovascularization secondary to age-related macular degeneration